The increasing investment in R&D and growing geriatric population are projected to fuel the growth of the global freeze of gait market at a CAGR of 4.86% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published on the “Global Freeze of Gait Market”.

The freeze of gait market is estimated to register a CAGR of 4.86% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global freeze of gait market Teva Pharmaceuticals (Israel), Sun Pharmaceutical Industries Ltd (India), Viatris Inc (US), Gondola Medical Technologies SA (Switzerland), Gyenno Technologies Co., Ltd. (China), Beats Medical Limited (Ireland), Agilitas (Australia), Walk with Path (Vesterbro), MedEXO Robotics (Hong Kong), Ustep (US) and others.

Market Highlights

The global freeze of gait market is accounted for to register a CAGR of 4.86% during the forecast period and is estimated to reach USD 1.99 billion by 2032.

The major market growth trend is the increasing prevalence of freezing gait. The market space witnesses rising research and development activity of new therapeutics across the globe. Thus, the growing number of strategic initiatives by the major players are driving growth for the freeze of gait market. Another key growth factor promoting an exponential increase in Year on Year (%) growth is the rising geriatric population lead to risk freeze of gait.

Furthermore, raising awareness about the treatment of freezing gait, increasing government funding for research are propelling the growth of the freezing gait market. However, side effects of drugs are expected to hamper the growth of the global market. Nevertheless, the technological advancements and new product launches are projected to create lucrative opportunity pockets for market players. We estimate a more focused business initiates targeting the same would result in greater revenue pockets for market players.

Segment Analysis

The global freeze of gait market is segmented into type, end user, and region. Based on type, the market is segmented into oral dopaminergic medication, wearable and walking aid devices, deep brain stimulation, and others. The wearable and walking aid devices segment was attributed to holding the largest market share in 2022 with a market share of over 40% as estimated by MRFR analysts.

Wearable and walking aid devices are the largest and fastest-growing segment, due to easy to use, increasing disability case across the globe as well as increasing cases on uncontrollable moments are raise the demand of wearable and walking aid devices. Wearable and walking devices easily track the patient’s health and technological advancement in wearable and walking devices are further drive the growth of this segment.

Further, we estimate that the market segment will continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet to witness continuous technological development in terms of new products launches. 

Further, based on the end user, the market is segmented into hospitals, clinics, and others. Hospitals segments are projected to have the largest market share during the forecast period owing to it being the most preferred setting to receive consultation and care.

Access full report @ https://www.marketresearchfuture.com/reports/freeze-of-gait-market-12099

Regional Analysis

The global freeze of gait market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.

the business presence of major key players, rising FDA approval, and increasing awareness about the medication and therapies, and rising prevalence of Parkinson disease in the region drive the regional market growth during the forecast period. In 2022, as per the Parkinson's Foundation, an estimated 90,000 suffered from Parkinson disease in the US people are affected by Freeze of Gait in the US, and this denotes a steep 50% growth from the earlier estimated rate of 60,000 diagnoses annually which is contributing to market growth over the forecast period.

Moreover, the Europe market has been persistently growing owing to factors such as the increasing healthcare expenditure, rising demand for advanced therapeutics, and increasing geriatric population lead to risk of Parkinson disease associated freeze of gait which drive the growth of freeze gait in Europe region. Moreover, accessibility to advanced diagnosis & treatment facilities, the rising geriatric population prone to Freeze of Gait is driving up demand for effective treatment & therapeutics, and growing healthcare expenditure. For instance, In 2021, according to the AGE Platform Europe, around 1.2 million patients suffered from Parkinson disease in Europe. Thus, increasing geriatric population, rising research and development activity positively impact on the growth of freeze of gait market. Additionally, developing government support and rising freeze gait awareness program are boosting the growth of the Freeze of Gait market in Europe.

Additionally, market factors, such as the growth in medical facility infrastructure, increasing government initiative for freeze gait treatment, presence of large patient pool of Parkinson disease associated with freeze of gait are positively impact on the growth of freeze of gait market in Asia-Pacific region. Furthermore, availability of cheap labour cost, increasing interest of major key players for investment in Asia-Pacific region are further drive the growth of this market.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The market factors such as rising government support for business establishment of key players, rising incidence of freeze of gait limited increasing number of research companies and subsidiaries involved in R&D, and increasing initiatives are taken by Middle East countries to develop their healthcare infrastructure. Moreover, growing awareness and demand from the general population for effective treatments are likely to favor market growth.

Key Findings of the Study

• The global freeze of gait market is expected to reach USD 1.19 billion by 2032, at a CAGR of 4.86% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, the development of medical facility, rising out of pocket expenditure drive the growth of freeze of gait market in Asia-Pacific region.


• Based on type, the wearable and walking aid devices segment was attributed to holding the largest market in 2022, with an approximate market share of 48.6%.


• Teva Pharmaceuticals (Israel), Sun Pharmaceutical Industries Ltd (India), Viatris Inc (US), Gondola Medical Technologies SA (Switzerland), Gyenno Technologies Co., Ltd. (China), Beats Medical Limited (Ireland), Agilitas (Australia), Walk with Path (Vesterbro), MedEXO Robotics (Hong Kong), Ustep (US)